People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kriya Therapeutics, Inc. | — | Biotechnology | Series D+ | $870.3M | $2.5B | 2022 |
Ilise Lombardo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ilise Lombardo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Saira Ramasastry | 1 | 4 |
| DANIEL CHEN | 1 | 3 |
| Roger Jeffs | 1 | 3 |
| Dana Johnson | 1 | 3 |
| Ilan Oren | 1 | 2 |
| Ryan Gallagher | 1 | 2 |
| James Momtazee | 1 | 2 |
| Keith Manchester | 1 | 1 |
| Katherine Eade | 1 | 1 |
| C.R. Sincock | 1 | 1 |
| Akshay Rai | 1 | 1 |
| Shankar Ramaswamy | 1 | 1 |
| Curt Herberts | 1 | 1 |
| Britt Petty | 1 | 1 |
| Brian Furmanski | 1 | 1 |
| Trit Garg | 1 | 1 |
| Neelaksh Varshney | 1 | 1 |
| Michele Stone | 1 | 1 |
| Neera Ravindran | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.